Washington, D.C. – Today, U.S. Senators Susan Collins (R-ME) and Jeanne Shaheen (D-NH), Co-Chairs of the U.S. Senate Diabetes Caucus and senior members of the U.S. Senate Appropriations Committee, responded to new data from the American Diabetes Association that shows the cost of diabetes in America, including the cost of insulin, continues to skyrocket for patients and the federal government.
“Access to insulin is a life-or-death concern for many of the millions of Americans living with diabetes. Today’s report further emphasizes our need to immediately lower skyrocketing costs to ensure this critical medicine is never out of reach for those who need it. With spending on insulin tripling in the past 10 years, it’s time Congress acts. That’s why we introduced the INSULIN Act earlier this year, and we urge our colleagues to work with us to get this bill passed as soon as possible so we reduce the financial burdens placed on those with diabetes and their families,” said Senators Collins and Shaheen.
According to the report:
As co-chairs of the Senate Diabetes Caucus, Collins and Shaheen have worked together to increase awareness of the threats posed by diabetes, invest in research and improve access to treatment options. Earlier this year, Collins and Shaheen introduced the INSULIN Act, which would comprehensively address the skyrocketing costs of insulin and remove barriers to care making it more accessible to millions of Americans. They recently joined a Washington Post Live event to discuss their efforts to lower the cost of insulin and prescription drugs. The senators have consistently pressed to hold insulin manufacturers, insurers and pharmacy managers accountable for the skyrocketing cost of life-saving insulin.